Heike Pfeifer

发表

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, M. Schmid, O. Ottmann, 2006, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, O. Ottmann, M. Bornhäuser, 2006, Blood.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, M. Schmid, O. Ottmann, 2006, Blood.